One more takeaway from this interview was the 4th bullet point- 3 cohorts of dose expansion have completed without any DLTs or safety concerns.
I also liked 3 bullet points on the anatomical, molecular and biochemical responses which wraps up the conclusions nicely IMO:
CU6 - Media and Industry News, page-383
-
- There are more pages in this discussion • 198 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.97 |
Change
-0.150(2.11%) |
Mkt cap ! $2.228B | |||
| Open | High | Low | Value | Volume |
| $7.01 | $7.14 | $6.76 | $12.67M | 1.830M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 27392 | $6.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.99 | 1432 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |